- FDA Approved a Neurostimulation Therapy for Major Depressive Disorder
- What is the research progress of immunotherapy for Alzheimer’s disease?
- Protein linked to significantly increased risk of Alzheimer’s disease
- How much do you know about monkeypox?
- COVID-19 linked to dramatic increase in type 1 diabetes in children: up to 72%
- New therapy may conquer cancer with herpes virus
These three drugs have been shown to be ineffective in treating COVID-19
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
These three drugs have been shown to be ineffective in treating COVID-19.In the face of the sudden outbreak of COVID-19, the new use of old drugs has become the main way to find treatment options for COVID-19.
Through rigorous clinical research design: randomized, double-blind, placebo-controlled large-sample multi-center clinical trials, medical scientists have found a series of old drugs that reduce the mortality rate of severe COVID-19 patients, the most typical of which is dexamethasone, which is cheap Another easy-to-obtain old drug: the clinical trial results are released at noon, and the UK will be promoted nationwide in the afternoon.
However, more older medicines have proven ineffective for quality COVID-19.
On August 18, 2022, the COVID-OUT clinical research group led by the University of Minnesota reported in the New England Journal of Medicine (NEJM) the results of a large-scale clinical trial of the new use of old drugs to treat COVID-19 .
This large randomized placebo-controlled Phase 3 clinical trial (NCT04510194) evaluated 3 of the frequently discussed drugs: metformin, ivermectin and fluvoxamine. 1323 patients with COVID-19 shortly after diagnosis were enrolled, with a median age of 46 years and 56% women. 52% were vaccinated.
The study found that compared with the control group, the adjusted risk factors for disease progression after metformin use aOR=0.84, p=0.19; ivermectin aOR=1.05, p=0.78; fluvoxamine aOR=0.94, p=0.75. None of the three drugs had a significant benefit in improving patient symptoms and clinical manifestations.
The study further found that there was no significant reduction in hospitalization and death among patients receiving the three drugs, aOR=0.47; ivermectin aOR=0.73; fluvoxamine aOR=1.11.
The study found that none of the three drugs , metformin, ivermectin, and fluvoxamine, improved symptoms early at diagnosis, nor did they reduce hospitalizations and deaths.
For a new disease such as COVID-19, doctors can only diagnose and treat based on the consensus formed by the best evidence currently available at the beginning; then adjust or improve it when new evidence is available.
In the process of repeated verification, especially relying on the results of RCT research, medicine has been advanced; finally, empirical medicine has been transformed into evidence-based medicine.
[ 1] https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
(source:internet, reference only)